One Nucleus announces formal Partnership with the newly created Cambridge New Therapeutics Forum

One Nucleus is delighted to announce that it is a formal, founding partner of the Cambridge New Therapeutics (CamNTF). 
CamNTF is the brainchild of several fantastic Cambridge-based scientists. Its purpose is to promote interactions between scientists throughout the region, creating new opportunities for biomedical research and development. 
It is a forum open to all scientists in Cambridge and the surrounding area who are interested in research and development of new therapeutics.  Scientists at the University of Cambridge, local research institutes, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations and other life-science R&D organisations are most welcome to join.
One Nucleus is supporting CamNTF with expertise in events and promotion, encouraging our networks and members in the UK and beyond to become involved.  

There will be 5 meetings in 2015. The first took place at MedImmune in early March with Mene Pangalos and Jane Osbourn delivering key presentations to an 80 strong audience. The next meeting will be hosted by the Babraham Institute on 28 April and will feature  talks by Dr Xavier Jacq, Head of Biology (MISSION Therapeutics), an experienced drug discovery project manager and expert in protein ubiquitylation and Dr Klaus Okkenhaug, Group Leader at Babraham Institute, an immunologist with particular interests in cell signalling and PI3-kinases. 
David Rees, Founder of CamNTF commented, “Cambridge has become an internationally leading hub for biomedical research and this forum is an opportunity for scientists interested in new therapeutics to increase interactions”. 

Harriet Fear, Chief Executive of One Nucleus explains, ”Cam NTF is an important part of the local eco-system. With an ever-changing and dynamic sector here, the cross fertilisation of ideas, concepts and innovations among the audience will certainly lead to even greater collaboration in the community. One Nucleus is delighted to be providing our support and advice”.

About One Nucleus
One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster. 

Vision: For One Nucleus and our members to be the top European life science and healthcare network
Mission: We will achieve this by maximising the global competitiveness of our members. 

About Cambridge New Therapeutics Forum
A scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotech’s, CROs, and not-for-profit organisations.

The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development.

Starting from 2015 CamNTF will host early-evening meetings open to all scientists interested in research into new therapeutics. These will rotate around different organisations located in the Cambridge biotech cluster. Each two-hour session will begin with two short scientific presentations and will be followed by networking and snacks (6pm-8pm). 

Attendance is free but all attendees must register in advance.  Places are limited and early registration will be important to avoid disappointment! Registration closes one week prior to the meeting.

Scientific Sponsors
Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry),
Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners),
Professor Michael  Wakelam (Babraham Institute, Director),
Professor Ewan Birney (EMBL-EBI, Associate Director),
Dr Mene Pangalos (AstraZeneca, R&D Director),
Dr David Rees (Astex Pharmaceuticals) 
Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).

Operational organising committee
Dr David Rees (Astex)
Dr Simon Cook (Babraham Institute)
Dr Ruth March (AstraZeneca)
Dr Chuck Cook (EMBL-EBI)
Dr Jana Voigt (CUHP OTR)

Leave a Reply